跳至主要内容
临床试验/ITMCTR2100004996
ITMCTR2100004996尚未招募4 期

A randomized, controlled, multicentre clinical study of Shengu Capsule in the treatment of postmenopausal osteoporosis (deficiency syndrome of liver and kidney)

Fujian Academy of Chinese Medical Sciences0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
45 至 70(—)
性别
Female

入选标准

  • 1.Meet the diagnostic criteria for postmenopausal osteoporosis;
  • 2.Meet the TCM syndrome differentiation standard of liver and kidney deficiency;
  • 3.Voluntarily signed informed consent;
  • 4.Age between 45 and 70 years old;
  • 5.Female have been naturally menopausal for more than 1 yearr.

排除标准

  • 1.Those with secondary osteoporosis such as hyperparathyroidism, rheumatoid arthritis, multiple myeloma, type I diabetes, etc;
  • 2.People with mental illness or Alzheimer's;
  • 3.People with allergies or those who are known to be allergic to the ingredients in this medicine;
  • 4.Those who are in a critical condition and are difficult to make an accurate assessment of the effectiveness and safety of the drug;
  • 5.Patients with hypercalcemia and hypercalciuria.

研究者

发起方
Fujian Academy of Chinese Medical Sciences

相似试验

A randomized, controlled, multicentre clinical study... | 临床试验